Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-24T01:10:13.869Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication

Published online by Cambridge University Press:  16 April 2020

L Conlon ,
T.J Fahy ,
R. OˈToole ,
J. Gilligan  and
P. Prescott
L Conlon*
Affiliation:
Department of Psychiatry, Clinical Sciences Institute, University College Hospital, Galway, Ireland
T.J Fahy
Affiliation:
Department of Psychiatry, Clinical Sciences Institute, University College Hospital, Galway, Ireland
R. OˈToole
Affiliation:
Department of Psychiatry, Clinical Sciences Institute, University College Hospital, Galway, Ireland
J. Gilligan
Affiliation:
Department of Psychiatry, Clinical Sciences Institute, University College Hospital, Galway, Ireland
P. Prescott
Affiliation:
Faculty of Mathematical Studies, University of Southampton, Southampton, UK
*
*Corresponding author. E-mail address:louiseconlon@eircom.net (L. Conlon).
Get access

Summary

Little information exists on the medium- to long-term outcome of switching patients with schizophrenia from traditional depot to atypical oral antipsychotic agents. By detailed clinical audit, we identified a representative group of 102 patients of an Irish psychiatric service with DSM-IV chronic schizophrenia and on depot neuroleptics for a mean of 15 years. Of 69 eligible to participate, 33 entered a 6-month switch study of risperidone, with limited follow-up of consenters and non-consenters at 1 and 2 years. At 6 months, 23 of 33 were still on risperidone and had small significant improvements in clinical and extrapyramidal side effects, QOL and adjunct medication measures over baseline. At 12 months, 19 of 33 were still on risperidone, reducing to 13 of 33 at 2 years. At 2 years, of 32 surviving consenters to switch, 19 had suffered clinically detrimental events and were no longer on risperidone, compared to none of the 33 surviving non-consenters, who were all still on depot. These findings suggest that switching from depot to risperidone may encounter high rates of refusal and attrition subsequent to switch. While a majority of switched patients may improve after to least 6 months, audit plus switch may have clinically unfavourable effects on others over a 2-year follow-up period.

Keywords

RisperidoneSchizophreniaDepotAuditSwitch studyFollow-up
Type
Original Article
Information
European Psychiatry , Volume 17 , Issue 8 , December 2002 , pp. 459 - 465
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, D., Addington, J., Schissel, B.A depression rating scale for schizophrenics. Schizophr Res 1990;3:247–51.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Global assessment of functioning, Axis IVDiagnostic and statistical manual of mental disorders Washington (DC): APA; 1994 4th ed..Google Scholar
Andreasan, N.C.The scale for the assessment of negative symptoms (SANS) Iowa City (IO): The University of Iowa; 1983.Google Scholar
Barnes, T.A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672–6.CrossRefGoogle ScholarPubMed
Chouinard, G., Ross-Chouinard, A., Annable, L., Jones, B.D.The extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7(3): 233Google Scholar
David, A.S.Insight and psychosis. Br J Psychiatry 1990;156:798–808.CrossRefGoogle ScholarPubMed
Desai, N.M., Huq, Z., Martin, S.D., McDonald, G.Switching from depot antipsychotic to risperidone: results of a study of chronic schizophrenia. Adv Ther 1999;16(2):78–88.Google ScholarPubMed
Heinrichs, D.W., Hanlon, E.T., Carpenter Jr, W.T.The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388–98.CrossRefGoogle ScholarPubMed
Hogan, T.P., Awad, A.G., Eastwood, R.A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol M 1983;13:177–83.CrossRefGoogle ScholarPubMed
Jeste, D.V., Klausner, M., Brecher, M.A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicentre trial. Psychopharmacology 1997;131:239–47.CrossRefGoogle Scholar
Kay, S.R., Fiszbein, A., Opler, L.A.The positive and negative syndromescale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.CrossRefGoogle Scholar
Kemp, R., Hayward, P., Applewhaite, G.Compliance therapy in psychotic patients: randomised controlled trial. Br Med J 1996;312:345–9.CrossRefGoogle ScholarPubMed
Kirov, G.K., Murray, R.M., Seth, R.V., Feeney, S.The Risperidone Switching Study Group. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439–43.CrossRefGoogle ScholarPubMed
Larsen, E.B., Gerlach, J.Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996;93:381–8.CrossRefGoogle ScholarPubMed
McGrath, J., Emmerson, W.B.Treatment of schizophrenia. Br Med J 1999;319:1045–8.CrossRefGoogle ScholarPubMed
Periera, S., Pinto, R.A survey of the attitudes of chronic psychiatric patients living in the community towards their medication. Acta Psychiatr Scand 1997;95:464–8.CrossRefGoogle Scholar
Simpson, G.M., Angus, J.W.S.A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970 (Suppl 212):11–9.CrossRefGoogle ScholarPubMed
US Department of Health, Education and Welfare. Abnormal involuntary movement scale (AIMS). In: Guy, WECDEU Assessment Manual. 1976. p. 534–7.Google Scholar
Walburn, J., Gray, R., Gournay, K., Quaraishi, S., David, A.S.Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300–7.CrossRefGoogle ScholarPubMed
Wilkinson, G., Hesdon, B., Wild, D., Cookson, R., Farina, C., Sharma, V.Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000;177:42–6.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.